Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange

Area of Science:

• Hematology
• Oncology
• Nephrology

Background:

• Drug-associated thrombotic microangiopathy (TMA) is a rare but serious adverse event.
• It is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ damage.
• Multiple myeloma treatments, including proteasome inhibitors, can be associated with TMA.

Observation:

• A patient with relapsed multiple myeloma was treated with carfilzomib.
• During the first cycle of carfilzomib therapy, the patient developed symptoms consistent with TMA.
• Clinical presentation included thrombocytopenia, anemia, and renal dysfunction.

Findings:

• The patient's presentation strongly suggested drug-induced TMA.
• Carfilzomib was identified as the likely causative agent.
• This case highlights a potential complication of carfilzomib treatment.

Implications:

• Early recognition and management of carfilzomib-associated TMA are crucial.
• This case underscores the importance of monitoring for TMA in patients receiving carfilzomib.
• Further research may elucidate the mechanisms and optimal treatment strategies for drug-associated TMA.